A complex translocation (9;22;16)(q34;q11.2;p13) in chronic myelocytic leukemia.
The t(9;22) is present in almost all cases with chronic myelocytic leukemia (CML). Around 5% of these patients show complex translocations involving a third chromosome in addition to chromosomes 9 and 22. All chromosomes have participated in these variants and the BCR-ABL1 hybrid gene is always present. We describe a CML case with a new complex t(9;22;16)(q34;q11.2;p13). Seven months after imatinib treatment a karyotype showed the appearance of a clone with a standard t(9;22) in addition to the clone with the complex translocation. The b3a2 transcript of BCR-ABL1 was detected both at diagnosis and 7 months after therapy. In CML, both complex translocations and standard translocations have the same prognosis. However, these complex variants could contribute to the tumoral evolution by conferring selective advantages that, in turn, cause the preferential manifestation at diagnosis of clones with complex translocations.
Espinoza
Juan Pablo Meza
JP
Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Cárdenas
Verónica Judith Picos
VJ
Jiménez
Erika Alejandra Vásquez
EA
Angulo
Melva Gutiérrez
MG
Flores
María Amparo Esparza
MA
García
Juan Ramón González
JR
D002675:Child, Preschool; D002871:Chromosome Banding; D002885:Chromosomes, Human, Pair 16; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic
D016044:Fusion Proteins, bcr-abl